Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: zeta1961 who wrote (23354)	3/29/2007 3:56:23 PM
From: zeta1961	Read Replies (1) \| Respond to of 52153

Final vote question: "Is there substantial evidence that product works?" 13-4 with proviso that 9902B is completed and efforts to recruit from minority populations..

To: zeta1961 who wrote (23354)	3/29/2007 7:00:04 PM
From: Biomaven	Read Replies (1) \| Respond to of 52153

Much appreciate this Elisabeth - nice to get the running commentary. Now I wonder what the FDA will do here - it's not a foregone conclusion they will approve the drug although there clearly will be pressure for them to do so. I guess the shorts underestimated the impact of the hard survival data here. At the end of the day that's an unarguable endpoint - the PFS and other pre-specified surrogates specified in the trial are all very well in theory but are weakly linked to survival. Peter